Last update: Dec. 27, 2019

Brivaracetam

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Análogo del Levetiracetam, antiepiléptico de uso autorizado en Europa en niños a partir de 4 años de vida.
Administración oral o intravenosa en dos dosis diarias.

A fecha de última actualización no encontramos datos publicados sobre su excreción en leche materna.

Su análogo, el Levetiracetam, con el que comparte casi idénticos datos de farmacocinética, se excreta en pequeña cantidad en leche materna.

Se ha utilizado, con buena tolerancia, a dosis de 2 mg/kg dos veces al día, en lactantes a partir de 1 a 3 meses de edad (Liu 2019, Schoemaker 2017).

Autores expertos consideran compatible o muy probablemente compatible el uso de esta medicación durante la lactancia (Cabo 2019).


See below the information of this related product:

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Brivaracetam in other languages or writings:

Group

Brivaracetam belongs to this group or family:

Tradenames

Main tradenames from several countries containing Brivaracetam in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 212 daltons
Protein Binding 20 %
VD 0,5 l/Kg
Tmax 1 hours
T1/2 7 - 9 hours

References

  1. Liu E, Dilley D, McDonough B, Stockis A, Daniels T. Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial. Paediatr Drugs. 2019 Aug;21(4):291-301. Abstract
  2. Cabo-Lopez I, Canneti B, Puy-Nunez A. [Epilepsy and breastfeeding: from myth to reality]. Rev Neurol. 2019 Jul 16;69(2):68-76. Abstract
  3. Schoemaker R, Wade JR, Stockis A. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. Eur J Clin Pharmacol. 2017 Jun;73(6):727-733. Abstract
  4. EMA. Brivaracetam (Briviact). Ficha técnica. 2016 Full text (in our servers)
  5. EMA. Brivaracetam (Briviact). Drug Summary. 2016 Full text (in our servers)

Total visits

31

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche de Euskadi

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM